新型抗抑郁药物分子靶标研究进展  

Advances in Novel MolecularTargets for Antidepressants

作　　者：余旭奔 杜贯涛[2] 刘广军[2] 洪浩[1] 

机构地区：[1]中国药科大学药学院药理系,江苏南京210009 [2]南京医科大学附属常州市第二人民医院药学部,江苏常州213003

出　　处：《药学进展》2016年第8期577-582,共6页Progress in Pharmaceutical Sciences

基　　金：江苏省自然科学基金项目(No.SBK201320969);国家自然科学基金面上项目(No.81273497;NO.81573413)

摘　　要：抑郁症是一种严重的精神障碍疾病,其发病机制复杂。近年来随着对抑郁症发病机制的深入研究,发现了一些基于非单胺递质的新型抗抑郁药物分子靶标。综述N-甲基-D-天冬氨酸(NMDA)受体、促肾上腺皮质激素释放因子(CRF)受体、阿片受体、γ-氨基丁酸B(GABAB)受体、乙酰胆碱受体等抗抑郁药物作用的新靶标及其相应分子机制研究进展,为开发高效、安全的抗抑郁症新药提供参考。Depression is a serious mental disorder with complex pathogenesis. In recent years, with in-depth study on the pathogenesis of depression, some novel molecular targets for antidepressants based on ＂monoaminergic hypothesis＂ were discovered. This paper reviewed these novel molecular targets such as NMDA receptor, CRF receptor 1, opioid receptor, GABAB receptor, and acetylcholine receptor, as well as their corresponding mechanisms, so as to provide references for developing highly effective and safe antidepressants.

关 键 词：抑郁症 NMDA受体 CRF受体 阿片受体 GABAB受体 乙酰胆碱受体 

分 类 号：R971.43[医药卫生—药品]